Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Rationale To assess the paroxetine-induced serotonin transporter (SERT) occupancy (SERTocc) using in vivo (123)I-ADAM SPECT.Objectives (123)I-ADAM SPECT was used to investigate the SERTocc induced by paroxetine in major depression disorder (MDD) patients, to compare the SERT availability in drug-free MDD patients and healthy volunteers, and to study the relationship between paroxetine plasma concentrations (Cp) and SERTocc.Materials and methods Measures of SERT availability by means of (123)I-ADAM SPECT were obtained in ten MDD patients before and after 4- to 6-week treatment with paroxetine 20 mg/day. (123)I-ADAM SPECT measures of SERT availability from a group of ten previously studied age-matched healthy volunteers were used for comparison. The relationship between percentages of SERTocc and paroxetine Cp was studied using an E (max) model.Results Mean SERTocc values were 66.4 +/- 9.5% in midbrain, 63.0 +/- 9.6% in thalamus, and 61.3 +/- 10.9% in striatum. No significant differences in SERTocc were found among these three regions. No significant differences in mean SERT availability were found in any region between drug-free MDD patients (midbrain = 1.14 +/- 0.15; thalamus = 0.85 +/- 0.13; striatum = 0.70 +/- 0.07) and healthy volunteers (midbrain = 1.19 +/- 0.22; thalamus = 0.96 +/- 0.14; striatum = 0.67 +/- 0.15). The E (max) model returned a SERTocc(max) = 70.5% and a Cp(50) = 2.7 ng/ml.Conclusions Using (123)I-ADAM SPECT, treatment with paroxetine 20 mg/day leads to more than 60% SERTocc on average in cerebral regions with known high SERT density. Data from this study do not support the existence of SERT availability differences between drug-free MDD patients and healthy volunteers. Finally, the E (max) model is suitable for the study of paroxetine Cp relationship to (123)I-ADAM SPECT-measured SERTocc. This approach may be useful for pharmacokinetic-pharmacodynamic relationships in drug development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a total of 16 articles (reporting on 17 unique studies) were included [17–19, 28–40].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [32]
In the citing paper
“Eight studies excluded participants taking other possibly interacting medications (e.g., other psychotropic drugs or substances with high affinity for SERT) [19, 31, 32, 37–40, 42].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [32]
In the citing paper
“There is no firm evidence that clinical efficacy [1, 17, 45], nor adverse effects are dependent on SERT occupancy; the studies included in the present review that measured the relationship between clinical effect and SERT occupancy did not find significant correlations [17, 32, 37, 38, 48].”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [32]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter
Owens, M. J., & Nemeroff, C. B. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.2.288 · Cited by 929
Kapur, S., Zipursky, R. B., & Remington, G. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 712
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 1×
“Meyer et al. 2004a PET 11 C-DASB 29 c 35 Striatum No changes”
BackgroundMalison, R. T., Price, L. H., Berman, R., van Dyck, C. H., Pelton, G. H., Carpenter, L., Sanacora, G., Owens, M. J., Nemeroff, C. B., Rajeevan, N., et al. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00272-8 · Cited by 496
Stockmeier, C. A. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00050-5 · Cited by 358
Laruelle, M., Baldwin, R. M., Malison, R. T., Zea‐Ponce, Y., Zoghbi, S. S., Al‐Tikeriti, M. S., Sybirska, E. H., Zimmermann, R. C., Wisniewski, G., Neumeyer, J. L., et al. (1993) · Synapse · doi:10.1002/syn.890130402 · Cited by 351
Meyer, J. H., Wilson, A. A., Ginovart, N., Goulding, V., Hussey, D., Hood, K., & Houle, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1843 · Cited by 340
Lower Serotonin Transporter Binding Potential in the Human Brain During Major Depressive Episodes
Parsey, R. V., Hastings, R. S., Oquendo, M. A., Huang, Y.-Y., Simpson, N., Arcement, J., Huang, Y., Ogden, R. T., Van Heertum, R. L., Arango, V., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.52 · Cited by 309
Research works printed but not linked: 1
- Ahonen A, Heikman P, Kauppinen T, Koskela A, Bergström K (2004) Serotonin transporter availability in drug free depression patients using a novel SERT ligand. Eur J Nucl Med 31:S227
Cited by
Meta-analysis of molecular imaging of serotonin transporters in major depression
Gryglewski, G., Lanzenberger, R., Kranz, G. S., & Cumming, P. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.82 · Cited by 227
Lanzenberger, R., Kranz, G. S., Haeusler, D., Akimova, E., Savli, M., Hahn, A., Mitterhauser, M., Spindelegger, C., Philippe, C., Fink, M., et al. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.07.023 · Cited by 139
Kambeitz, J. P., & Howes, O. D. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.07.034 · Cited by 96
Ruhé, H. G., Booij, J., Weert, H. C. V., Reitsma, J. B., Fransen, E. J. F., Michel, M. C., & Schene, A. H. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.148 · Cited by 73
Sørensen, A., Ruhé, H. G., & Munkholm, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01285-w · Cited by 65
Metadata
- Authors
- Catafau, A. M., Perez, V., Plaza, P., Pascual, J.-C., Bullich, S., Suarez, M., Penengo, M. M., Corripio, I., Puigdemont, D., Danus, M., Perich, J., & Alvarez, E.
- Affiliations
- GlaxoSmithKline (Spain) (ES)
- Hospital Del Mar (ES)
- Hospital de Sant Pau (ES)
- Corresponding author
- Catafau, Ana M.
- Venue
- Psychopharmacology
- Published
- 2006-10-11
- Volume
- 189
- Issue
- 2
- Pages
- 145-153
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2013861319
- Cited by
- 46
- References
- 35
- Citations by year
- 2023: 1 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 2 · 2017: 1 · 2015: 4 · 2014: 3 · 2013: 3 · 2012: 4
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- paroxetine, plasma drug concentration, Emax model, midbrain, thalamus, striatum, healthy volunteers comparison
- MeSH terms
- Adult, Brain, Cinanserin, Corpus Striatum, Depressive Disorder, Female, Humans, Iodine Radioisotopes, Male, Mesencephalon, Middle Aged, Radioligand Assay, Serotonin Antagonists, Thalamus, Tomography, Emission-Computed, Single-Photon, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Paroxetine, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. https://app.cochat.ai/papers/10.1007/s00213-006-0540-y
- The paper
- Catafau, A. M., Perez, V., Plaza, P., Pascual, J.-C., Bullich, S., Suarez, M., Penengo, M. M., Corripio, I., Puigdemont, D., Danus, M., Perich, J., & Alvarez, E. (2006). Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. Psychopharmacology. https://doi.org/10.1007/s00213-006-0540-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.